|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
3.68/6.50
|
企業價值
14.01B
|
資產負債 |
每股賬面淨值
23.71
|
現金流量 |
現金流量率
0.05
|
損益表 |
收益
1.89B
|
每股收益
17.73
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/03 01:27 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |